-
Mashup Score: 0Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML - 8 hour(s) ago
Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
John M. Burke, MD, discusses results from a US community-based healthcare practitioner survey on challenges in initiating venetoclax for patients with CLL. @ASH_hematology @TheUSONetwork #ASH24 #leusm Watch here: https://t.co/NEzixGTjRI
-
-
Mashup Score: 0
Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, can improve survival outcomes over CIT in treatment-naive CLL.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Fixed-duration acalabrutinib plus venetoclax, with or without obinutuzumab, can improve survival outcomes over chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia. Presented at #ASH24 by Dr Jennifer Brown from @DanaFarber. #leusm https://t.co/GMMYpe4F8x https://t.co/69hhTnWEsQ
-
-
Mashup Score: 4
Fedratinib reduced symptoms and spleen volume in patients with MDS or MPNs in a phase 2 trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet-
Fedratinib reduced symptoms and spleen volume in patients with MDS or MPNs in a phase 2 trial. Presented at #ASH24 by @KuykendallMd from @MoffittNews. #leusm https://t.co/2kd027QED8 https://t.co/xCoT5DA064
-
-
Mashup Score: 4Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL - 6 day(s) ago
Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL @ASH_hematology @mshadman @fredhutch #ASH24 #leusm https://t.co/u88By9fm1n
-
-
Mashup Score: 1
Blinatumomab plus chemotherapy represents a new standard of care for most children with NCI standard-risk B-cell ALL, according to Rachel E. Rau, MD.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Oncologists1Tweet-
Blinatumomab plus chemo represents a new standard for most kids with NCI standard-risk B-ALL, according to @RachelRau3 from @seattlechildren. She presented results with this combo (from the AALL1731 trial) at #ASH24. #leusm https://t.co/Zvx4CUWgrw https://t.co/VjVazE9w2G
-
-
Mashup Score: 0
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Source: www.cancernetwork.comCategories: General Medicine News, Oncologists1Tweet-
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study. #ASH24 #leusm | @ASH_hematology https://t.co/0dce5ckSbl
-
Tune in to hear as Eunice S. Wang, MD, of @RoswellPark, discusses ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia. @ASH_hematology #ASH24 #leusm Watch here: https://t.co/6wCu6Ebbj6